Novel therapies for diabetic retinopathy
| Autor: | Magdalena Kupis, Katarzyna Samelska, Jacek Szaflik, Piotr Skopiński |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Central European Journal of Immunology, Vol 47, Iss 1, Pp 102-108 (2022) |
| Druh dokumentu: | article |
| ISSN: | 1426-3912 1644-4124 |
| DOI: | 10.5114/ceji.2022.112993 |
| Popis: | Diabetes mellitus (DM) is a metabolic disease characterized by high blood glucose levels as well as microvascular and macrovascular changes. According to the latest statistics the growth of DM incidence is very fast. Diabetic retinopathy (DR) – one of the common DM complications – is the leading cause of blindness among professionally active people. Traditional treatment of DR including drugs controlling hyperglycemia, laser therapy, vitrectomy, and intravitreal injections of anti-VEGF is effectively administered with the effect of neovascularization and macular edema prevention. However, new potential DR therapies – focusing on a longer therapeutic effect and potentially fewer side effects – are being widely investigated. Gene therapy – targeting retinal vasculopathy or targeting retinal protection, mesenchymal stem cell injections, SGLT2 inhibitors, and islet cell transplantation have been proved to stop DR progression. The majority of the new treatment research was performed on an animal model and did not reach the final study stage. A further future human model and randomized studies with optimized delivery vectors will hopefully confirm positive outcomes of the new DR therapies. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|